



## **AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021**

November 1, 2021

BOSTON--(BUSINESS WIRE)--Nov. 1, 2021-- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021. AVEO's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, November 8, 2021, to discuss the financial results and provide a business update.

The call can be accessed by dialing (844) 882-7841 (U.S. and Canada) or (574) 990-9828 (international). The passcode for the conference call is 1647457. To access the live webcast, or the subsequent archived recording, please visit the Calendar of Events sub-section within the Investors section of the AVEO website at [www.aveooncology.com](http://www.aveooncology.com).

### **About AVEO Pharmaceuticals, Inc.**

AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA<sup>®</sup> (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.

### **Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the sections titled "Risk Factor Summary" and "Risk Factors" in AVEO's most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO's views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO's views as of any date other than the date of this press release.

Any reference to AVEO's website address in this press release is intended to be an inactive textual reference only and not an active hyperlink.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211101005200/en/): <https://www.businesswire.com/news/home/20211101005200/en/>

### **AVEO Public Relations:**

David Pitts, Argot Partners  
(212) 600-1902  
[aveo@argotpartners.com](mailto:aveo@argotpartners.com)

### **AVEO Investor Relations:**

Hans Vitzthum, LifeSci Advisors  
(617) 430-7578  
[hans@lifesciadvisors.com](mailto:hans@lifesciadvisors.com)

Source: AVEO Oncology